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KEYWORDS	
	 A	 series	 of	 new	 benzimidazole	 derivatives	 have	 been	 synthesized	 by	 simple	 condensation
reaction	 between	 benzimidazole	 derivatives	 and	 phenyl	 sulphonyl	 chloride	 derivatives.	 All
these	 compounds	were	 characterized	 by	 FT‐IR,	 1H	 NMR,	MS	 and	 elemental	 analysis.	 These
compounds	 were	 screened	 for	 antibacterial	 and	 antioxidant	 activities,	 respectively.	 The
antibacterial	 activities	 were	 compared	 with	 the	 standard	 drug	 such	 as	 chlorophenicol	 and
antioxidant	activities	were	compared	with	the	ascorbic	acid.	
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1.	Introduction	
	
Heterocyclic	 compounds	have	occupied	a	prominent	place	
among	various	classes	of	organic	compounds	by	virtue	of	their	
diverse	 biological	 activities.	 Hence	 the	 design,	 synthesis	 and	
production	 of	 new	 molecules	 for	 crop	 health	 and	 human	
welfare	 have	 taken	 center	 stage	 in	 recent	 years.	 Among	 the	
wide	 variety	 of	 heterocyclics	 that	 have	 been	 explored	 for	
developing	 pharmaceutically	 important	 role	 in	 medicinal	
chemistry	[1].	
Benzimidazole	 and	 its	derivatives	 are	of	 great	 importance	
in	 medicinal	 chemistry	 because	 of	 their	 wide	 variety	 of	
biological	 and	 pharmacological	 applications	 [1,2].	 The	
literature	survey	shows	several	examples	of	compounds	having	
a	benzimidazole	ring	which	exhibit	remarkable	bioactivity	that	
could	make	them	potentially	useful	in	the	treatment	of	cancer,	
and	cardiovascular	diseases	[3].	The	benzimidazole	unit	and	it’s	
derivatives	 possess	 anticancer	 [4],	 antiinflammatory	 [5],	
antibacterial	 [6],	 antifungal	 [7],	 antidiabetic	 [8],	 and	 anti‐HIV	
activities	 [9].	 On	 the	 basis	 of	 this	 observation	 we	 have	
synthesized	 benzimidazole	 derivatives	 as	 hitherto	 unreported	
analogues.		
Literature	 survey	 has	 also	 revealed	 the	 importance	 of	
benzimidazoles	 as	 antimicrobial	 and	 antioxidant	 agents	 [10‐
14].	 It	 has	 also	 been	 reported	 that	 certain	 substituted	
benzimidazole	derivatives	have	a	broad	antimicrobial	spectrum	
[11].	 Motivated	 by	 this	 above‐mentioned	 facts	 herein	 is	
reported	the	synthesis	and	antimicrobial,	anti	oxidant	activities	
of	new	benzimidazole	series.		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
All	the	reagents	were	purchased	from	Aldrich	Chemicals	Co,	
Loba	 Chemie.	 All	 the	 solvents	 and	 reagents	 used	 for	 the	
synthesis	and	analysis	were	of	analytical	grade.	The	progress	of	
the	reaction	and	the	purity	of	the	compounds	were	checked	by	
thin	 layer	 chromatography	 (TLC).	 1H	 NMR	 spectra	 were	
recorded	 on	 a	 BRUKER‐AV400	 spectrometer	 in	 CDCl3	 and	
tetramethylsilane	 (TMS;	 δ	 =	 0.00	 ppm)	 served	 as	 internal	
standards.	 IR	 spectra	 were	 measured	 using	 a	 JASCO	 FT/IR‐
4100	 spectrometer.	 Mass	 spectra	 were	 measured	 with	
Micromass	Q‐Tof.	CHNS	were	measure	by	the	Elementar	Vario	
EL	 III	 (Germany).	Thin‐layer	 chromatography	was	 carried	out	
using	SILICA	GEL	GF254.	The	melting	points	(uncorrected)	were	
measured	on	a	SALACO	apparatus.	
	
2.2.	Synthesis	
	
2.2.1.	General	procedure	for	the	synthesis	of	1‐(phenoxy	
carbonyloxy)ethyl	2‐ethoxy‐1‐((2'‐(1‐(phenylsulfonyl)‐1H‐
tetrazol‐5‐yl)	biphenyl‐4‐yl)methyl)‐1H‐benzo[d]imidazole‐
7‐carboxylate	derivatives	
	
The	 compound	 1‐(phenoxycarbonyloxy)ethyl	 1‐((2'‐(1H‐
tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐2‐ethoxy‐1H‐benzo[d]	
imidazole‐7‐carboxylate	 was	 purchased	 from	 Pure	 Chem.	
Scientific	 Limited,	 USA.	 Mixture	 of	 1‐(phenoxycarbonyl	
oxy)ethyl	 1‐((2'‐(1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐2‐
ethoxy‐1H‐benzo[d]imidazole‐7‐carboxylate	(0.2	g,	0.33	mmol),	
substituted	 phenyl	 sulfonyl	 chloride	 (0.36	mmol)	 and	 triethyl	
amine	 (0.66	mmol)	 in	 10	mL	 of	 dichloromethane	was	 stirred	
for	 2	 h	 at	 room	 temperature.	 After	 the	 completion	 of	 the	
reaction,	 5	 mL	 water	 was	 poured;	 the	 organic	 layer	 was	
extracted	 and	 distilled	 off	 completely	 to	 get	 product	 in	 good	
yield	(Scheme	1).		
1‐(Phenoxycarbonyloxy)ethyl‐2‐ethoxy‐1‐((2'‐(1‐(phenyl	
sulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)	 methyl)‐1H‐benzo[d]	
imidazole‐7‐carboxylate	(3a):	Color:	White.	Yield:	80%	(0.2	g).	
M.p.:	 78‐80	 oC.	 FT‐IR	 (KBr,	 cm‐1):	 1690	 (ketone	 CO	 stretch.),	
1700	(ester	CO	stretch.),	3030	(aromatic	CH	stretch.).	1H	NMR	
(400	MHz,	CDCl3,	δ,	ppm):	1.25‐1.32	(t,	3H,	CH3),	1.43‐1.45	(d,		
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Scheme	1
	
	
3H,	CH3),	2.9‐3.0	(q,	2H,	OCH2),	4.66	(s,	2H,	NCH2),	5.59‐5.67	(m,	
1H,	CH),	 6.81‐7.10	 (m,	 J	 =	7.5	Hz,	 2H,	 ArH),	7.12‐7.46	 (m,	 9H,	
ArH),	 7.58‐7.88	 (m,	 J	 =	 8	 Hz,	 10H,	 ArH).	 Anal.	 calcd.	 for	
C39H32N6O8S:	 C,	 62.89;	 H,	 4.33;	 N,	 11.28;	 S,	 4.31.	 Found:	 C,	
62.80;	H,	4.29;	N,	11.26;	S,	4.30%.	MS	(m/z):	(M+1)	745.79.	
1‐(Phenoxycarbonyloxy)ethyl	 2‐ethoxy‐1‐((2'‐(1‐(2‐nitro	
phenylsulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐1H‐
benzo[d]imidazole‐7‐carboxylate	 (3b):	 Color:	 Yellow.	 Yield:	
70%	 (0.18	 g).	M.p.:	 132‐134	 oC.	 FT‐IR	 (KBr,	 cm‐1):	 1450	 (NO2	
stretch.),	 1695	 (ketone	 CO	 stretch.),	 1710	 (ester	 CO	 stretch.),	
3040	(aromatic	CH	stretch.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
1.21‐1.23	 (t,	 3H,	 CH3),	 1.7‐2.0	 (d,	 3H,	 CH3),	 3.18‐3.21	 (q,	 2H,	
OCH2),	4.63	(s,	2H,	NCH2),	5.29‐5.47	(m,	1H,	CH),	6.89‐7.10	(m,	J	
=	7.2	Hz,	3H,	ArH),	7.14‐7.48	(m,	12H,	ArH),	8.28‐8.32	(m,	5H,	
ArH).	Anal.	calcd.	for	C39H31N7O10S:	C,	59.31;	H,	3.96;	N,	12.41;	S,	
4.06.	 Found:	 C,	 59.29;	 H,	 3.98;	 N,	 12.38;	 S,	 4.01%.	 MS	 (m/z):	
(M+1)	790.91.	
1‐(Phenoxycarbonyloxy)ethyl	 1‐((2'‐(1‐(2,5‐dichlorophenyl	
sulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐2‐ethoxy‐1H‐
benzo[d]imidazole‐7‐carboxylate	(3c):	Color:	White.	Yield:	76%	
(0.20	 g).	 M.p.:	 92‐94	 oC.	 FT‐IR	 (KBr,	 cm‐1):	 1710	 (ketone	 CO	
stretch.),	1729	(ester	CO	stretch.),	3039	(aromatic	CH	stretch.).	
1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.23‐1.24	(t,	3H,	CH3),	1.72‐
2.02	 (d,	3H,	CH3),	 3.17‐3.19	 (q,	2H,	OCH2),	 4.66	 (s,	 2H,	NCH2),	
5.27‐5.31	(m,	1H,	CH),	7.01‐7.12	(m,	J	=	7.2	Hz,	3H,	ArH),	8.01‐
8.11	 (m,	 7H,	 ArH),	 8.18‐8.29	 (m,	 9H,	 ArH).	 Anal.	 calcd.	 for	
C39H30Cl2N6O8S:	 C,	 57.57;	 H,	 3.72;	 N,	 10.33;	 S,	 3.94.	 Found:	 C,	
56.99;	H,	3.70;	N,	10.29;	S,	3.89%.	MS	(m/z):	(M+1)	814.22.	
1‐(phenoxycarbonyloxy)ethyl	 2‐ethoxy‐1‐((2'‐(1‐(3‐nitro	
phenylsulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐1H‐
benzo[d]imidazole‐7‐carboxylate	(3d):	Color:	White.	Yield:	72%	
(0.19	g).	M.p.:	98‐100	oC.	FT‐IR	(KBr,	cm‐1):	1445	(NO2	stretch.),	
1690	 (ketone	 CO	 stretch.),	 1700	 (ester	 CO	 stretch.),	 3039	
(aromatic	CH	stretch.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.18‐
1.20	 (t,	 3H,	 CH3),	 1.91‐2.01	 (d,	 3H,	 CH3),	 3.13‐3.15	 (q,	 2H,	
OCH2),	4.78	(s,	2H,	NCH2),	5.27‐5.29	(m,	1H,	CH),	7.11‐7.12	(m,	
3H,	ArH),	8.11‐8.17	(m,	7H,	ArH),	8.17‐8.28	(m,	10H,	ArH).	Anal.	
calcd.	 for	 C39H31N7O10S:	 C,	 59.31;	 H,	 3.96;	 N,	 12.41;	 S,	 4.06.	
Found:	C,	59.22;	H,	3.89;	N,	12.39;	S,	3.99%.	MS	 (m/z):	 (M+1)	
790.19.	
1‐(Phenoxycarbonyloxy)ethyl	 1‐((2'‐(1‐(4‐tert‐butylphenyl	
sulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐2‐ethoxy‐1H‐
benzo[d]imidazole‐7‐carboxylate	(3e):	Color:	White.	Yield:	86%	
(0.22	 g).	 M.p.:	 72‐74	 oC.	 FT‐IR	 (KBr,	 cm‐1):	 1700	 (ketone	 CO	
stretch.),	1729	(ester	CO	stretch.),	3050	(aromatic	CH	stretch.).	
1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	 1.13‐1.18	 (s,	 9H,	 3CH3),	
1.19‐1.20	(t,	3H,	CH3),	1.90‐2.01	(d,	3H,	CH3),	3.14‐3.15	(q,	2H,	
OCH2),	4.79	(s,	2H,	NCH2),	5.18‐5.20	(m,	1H,	CH),	7.10‐7.12	(m,	J	
=	 7.4	Hz,	 3H,	 ArH),	 8.15‐8.20	 (m,	 8H,	 ArH),	 8.20‐8.27	 (m,	 9H,	
ArH).	Anal.	calcd.	for	C43H40N6O8S:	C,	64.49;	H,	5.03;	N,	10.49;	S,	
4.00.	 Found:	 C,	 64.19;	 H,	 4.99;	 N,	 10.29;	 S,	 3.87%.	MS	 (m/z):	
(M+1)	801.73.	
1‐(Phenoxycarbonyloxy)ethyl	 2‐ethoxy‐1‐((2'‐(1‐tosyl‐1H‐
tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐1H‐benzo[d]imidazole‐7‐
carboxylate	(3f):	Color:	Yellow.	Yield:	78%	(0.19	g).	m.p.	87‐89	
oC.	FT‐IR	(KBr,	cm‐1):	1690	(ketone	CO	stretch.),	1710	(ester	CO	
stretch.),	 3041	 (aromatic	 CH	 stretch.).	 1H	 NMR	 (400	 MHz,	
CDCl3,	 δ,	 ppm):	 1.18‐1.20	 (t,	 3H,	 CH3),	 1.88‐1.91	 (d,	 3H,	 CH3),	
2.10	(s,	3H,	ArCH3),	3.14‐3.15	(q,	2H,	OCH2),	4.79	(s,	2H,	NCH2),	
5.17‐5.18	(m,	1H,	CH),	7.11‐7.12	(m,	J	=	8.0	Hz,	3H,	ArH),	8.11‐
8.16	 (m,	 8H,	 ArH),	 8.20‐8.25	 (m,	 9H,	 ArH).	 Anal.	 calcd.	 for	
C40H34N6O8S:	 C,	 63.31;	 H,	 4.52;	 N,	 11.08;	 S,	 4.23.	 Found:	 C,	
63.11;	H,	4.22;	N,	10.87;	S,	3.98%.	MS	(m/z):	(M+1)	759.80.		
1‐(Phenoxycarbonyloxy)ethyl	 1‐((2'‐(1‐(4‐chlorophenyl	
sulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐2‐ethoxy‐1H‐
benzo[d]imidazole‐7‐carboxylate	(3g):	Color:	White.	Yield:	78%	
(0.16	g).	M.p.:	138‐140	oC.	FT‐IR	(KBr,	cm‐1):	1690	(ketone	CO	
stretch.),	1710	(ester	CO	stretch.),	3041	(aromatic	CH	stretch.).	
1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.21‐1.23	(t,	3H,	CH3),	1.78‐
1.79	 (d,	3H,	 CH3),	 3.78‐3.80	 (q,	2H,	OCH2),	 4.82	 (s,	 2H,	NCH2),	
5.16‐5.17	(m,	1H,	CH),	7.10‐7.12	(m,	J	=	8.0	Hz,	3H,	ArH),	8.11‐
8.15	 (m,	 7H,	 ArH),	 8.20‐8.25	 (m,	 10H,	 ArH).	 Anal.	 calcd.	 for	
C39H31ClN6O8S:	 C,	 60.11;	 H,	 4.01;	 N,	 10.79;	 S,	 4.12.	 Found:	 C,	
60.07;	H,	3.71;	N,	10.29;	S,	3.82%.	MS	(m/z):	(M+1)	780.18.		
1‐(Phenoxycarbonyloxy)ethyl	2‐ethoxy‐1‐((2'‐(1‐(3‐(trifluoro	
methyl)	 phenylsulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐
1H‐benzo[d]imidazole‐7‐carboxylate	 (3h):	 Color:	 White.	 Yield:	
78%	(0.15	g).	M.p.:	 63‐65	 oC.	FT‐IR	 (KBr,	 cm‐1):	1695	 (ketone	
CO	 stretch.),	 1725	 (ester	 CO	 stretch.),	 3052	 (aromatic	 CH	
stretch.).	 1H	NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	 1.22‐1.23	 (t,	 3H,	
CH3),	 1.69‐1.71	 (d,	 3H,	 CH3),	 3.79‐3.81	 (q,	 2H,	 OCH2),	 4.79	 (s,	
2H,	NCH2),	5.28‐5.29	(m,	1H,	CH),	7.16‐7.18	(m,	J	=	6.9	Hz,	3H,	
ArH),	 8.16‐8.18	 (m,	 7H,	 ArH),	 8.19‐8.22	 (m,	 10H,	 ArH).	 Anal.	
calcd.	 for	C40H31F3N6O8S:	C,	59.11;	H,	3.84;	N,	10.34;	 S,	3.95%.	
Found:	 C,	 58.91;	 H,	 3.69;	 N,	 10.31;	 S,	 3.43.	 MS	 (m/z):	 (M+1)	
813.15.		
1‐(Phenoxycarbonyloxy)ethyl	 2‐ethoxy‐1‐((2'‐(1‐(4‐fluoro	
phenylsulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐1H‐
benzo[d]imidazole‐7‐carboxylate	 (3i):	Color:	White.	Yield:	78%	
(0.19	g).	M.p.:	80‐82	oC.		
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Table	1.	Antibacterial	activity	of	synthesized	compounds	*.	
Compound	
Bacillus	subtilis	 Klebsiellapneumoniae	 Xanthomonasvesicatoria	 Bacillus	cereus	 Shigellaflexneri	 Salmonella	Typhi	
5	mg	 10	mg 5	mg	 10	mg 5	mg 10	mg 5	mg 10	mg 5	mg	 10	mg	 5	mg	 10	mg
3a	 ‐	 ‐	 11	 10	 ‐	 ‐	 10	 ‐	 14	 ‐	 ‐	 ‐	
3b	 10	 ‐	 14	 10	 12	 ‐	 ‐	 ‐	 15	 14	 ‐	 ‐	
3c	 ‐	 ‐	 10	 ‐	 ‐ 10 11 12 10 ‐	 ‐	 ‐
3d	 12	 ‐	 ‐	 ‐	 10 10 16 ‐ 17 ‐	 ‐	 ‐
3e	 18	 ‐	 10	 ‐	 18 ‐ ‐ ‐ ‐ ‐	 ‐	 ‐
3f	 10	 ‐	 22	 ‐	 19 ‐ 10 ‐ ‐ ‐	 ‐	 ‐
3g	 10	 ‐	 16	 11	 10 ‐ ‐ ‐ 10 ‐	 ‐	 ‐
3h	 ‐	 ‐	 10	 10	 ‐ ‐ 17 ‐ 19 ‐	 ‐	 ‐
3i	 ‐	 ‐	 11	 10	 ‐	 ‐	 10	 ‐	 ‐	 ‐	 ‐	 ‐	
3j	 ‐	 ‐	 10	 14	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	 ‐	
Chloramphenicol	 31	 ‐	 37	 36	 30	 ‐	 37	 33	 36	 ‐	 ‐	 ‐	
*	Positive	control	zone	is	30	to	40	mm;	Standard	drug:	Chloramphenicol;	‘‐‘	=	Not	active.	
	
	
FT‐IR	 (KBr,	 cm‐1):	 1692	 (ketone	 CO	 stretch.),	 1723	 (ester	 CO	
stretch.),	 3049	 (aromatic	 CH	 stretch.).	 1H	 NMR	 (400	 MHz,	
CDCl3,	 δ,	 ppm):	 1.26‐1.28	 (t,	 3H,	 CH3),	 1.68‐1.70	 (d,	 3H,	 CH3),	
3.77‐3.78	 (q,	 2H,	OCH2),	 4.88	 (s,	 2H,	NCH2),	 5.27‐5.28	 (m,	 1H,	
CH),	6.98‐7.10	(m,	3H,	ArH),	8.00‐8.31	(m,	7H,	ArH),	8.42‐8.51	
(m,	10H,	ArH).	Anal.	calcd.	 for	C39H31FN6O8S:	C,	61.41;	H,	4.10;	
N,	11.02;	 S,	 4.20.	 Found:	C,	61.11;	H,	3.91;	N,	10.78;	 S,	 4.10%.	
MS	(m/z):	(M+1)	763.67.		
1‐(Phenoxycarbonyloxy)ethyl	 2‐ethoxy‐1‐((2'‐(1‐(2‐fluoro	
phenylsulfonyl)‐1H‐tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐1H‐
benzo[d]imidazole‐7‐carboxylate	 (3j):	Color:	White.	Yield:	72%	
(0.18	g).	M.p.:	118‐120	oC.	FT‐IR	(KBr,	cm‐1):	1691	(ketone	CO	
stretch.),	1719	(ester	CO	stretch.),	3039	(aromatic	CH	stretch.).	
1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.19‐1.21	(t,	3H,	CH3),	1.44‐
1.46	(d,	3H,	CH3),	3.1‐3.2	(q,	2H,	OCH2),	4.78	(s,	2H,	NCH2),	5.55‐
5.59	 (m,	 1H,	 CH),	 7.11‐7.13	 (m,	 2H,	 ArH),	 7.12‐7.38	 (m,	 8H,	
ArH),	8.98‐9.16	(m,	10H,	ArH).	Anal.	calcd.	for	C39H31FN6O8S:	C,	
61.41;	 H,	 4.10;	 N,	 11.02;	 S,	 4.20.	 Found:	 C,	 61.11;	 H,	 3.97;	 N,	
10.80;	S,	4.11%.	MS	(m/z):	(M+1)	763.28.	
	
2.3.	Biological	evaluation	‐	antibacterial	and	antioxidant	
activity	studies	
	
2.3.1.	Antibacterial	activity	
	
Antibacterial	 tests	 were	 carried	 out	 by	 disc	 diffusion	
method	using	100	µL	of	suspension	containing	106	cells/mL	of	
bacteria.	The	discs	(6	mm	diameter)	were	impregnated	with	5	
mg	 and	 10	 mg/mL	 of	 each	 compound	 and	 placed	 on	 the	
inoculated	 nutrient	 agar.	 Then,	 the	 inoculated	 plates	 were	
incubated	 at	 37±0.1	 oC	 at	 24	 h.	 One	 antibacterial	 drug,	
chloramphenicol,	also	is	used	as	positive	control.	Antibacterial	
activity	 was	 evaluated	 by	 measuring	 the	 zone	 of	 inhibition	
against	the	test	organisms.		
	
2.3.2.	Antioxidant	activity	
	
The	 DPPH	 assay	 was	 done	 by	 using	 solution	 of	 each	
compound	 made	 in	 methanol	 was	 added	 to	 95	 µL	 of	 DPPH	
solution	 (0.2	 mM/mL	 methanol)	 and	 mixed	 vigorously.	 The	
mixture	was	incubated	in	dark	at	room	temperature	for	30	min.	
Absorbance	 was	 measured	 at	 517	 nm	 using	 an	 Elisa	 reader.	
Ascorbic	acid	was	used	as	positive	control.		
The	 level	 of	 percentage	 inhibition	 of	 DPPH•	 by	 each	
compound	was	calculated	according	to	the	Equation	1.	
%	Radical	scavenging	=	[(AC	‐	A)/AC]	X	100	 	 (1)	
where	 AC	 is	 the	 absorbance	 of	 the	 control	 and	 A	 is	 the	
absorbance	 of	 sample.	 Percentage	 scavenging	 was	 also	
evaluated	in	ascorbic	acid	equivalence.	
	
	
	
	
3.	Results	and	discussion	
	
We	 have	 synthesized	 a	 series	 of	 1‐(phenoxy	
carbonyloxy)ethyl	 2‐ethoxy‐1‐((2'‐(1‐(phenylsulfonyl)‐1H‐
tetrazol‐5‐yl)	 biphenyl‐4‐yl)methyl)‐1H‐benzo[d]imidazole‐7‐
carboxylate	derivatives	using	a	known	procedure	and	obtained	
products	with	good	yield.	
The	 structures	 of	 all	 the	 synthesized	 compounds	 were	
characterized	 by	 spectroscopic	 data,	 and	 allowed	 these	
molecules	 for	 study	 of	 antibacterial	 and	 antioxidant	 activities	
(Table	1	and	2).	Benzimidazole	derivatives	shows	a	very	good	
anti	 bacterial	 activities	 [10‐14],	 we	 are	 comparing	 the	
synthesized	 new	 benzimidazole	 derivatives	 to	 the	 marketed	
chlorophenicol	 [15]	 which	 shows	 very	 good	 anti	 bacterial	
activity,	 here	 we	 are	 synthesizing	 the	 newly	 substituted	
benzimidazole	 derivatives	 for	 the	 studies	 of	 antibacterial	
activities	by	comparison	with	the	drug	molecule.	In	this	studies	
compound	 3f	 shows	 good	 bacterial	 activity,	 in	 which	 the	
tertiary	 butyl	 group	 is	 the	 electron	 releasing	 group,	 which	 is	
attached	 to	 the	 para	 position.	 The	 compound	 3i	 shows	 least	
antibacterial	 activity,	 in	which	 the	 fluoro	 group	 is	 attached	 to	
the	para	position,	which	is	the	electron	withdrawing	group.	The	
remaining	molecules	showing	the	moderate	activity.		
The	 synthesized	 compounds	 were	 tested	 for	 anti	 oxidant	
activities	 by	 evaluation	 with	 ascorbic	 acid	 [16,17].	 In	
antioxidant	 studies	 the	 compound	 3h	 shows	 the	 good	
antioxidant	 activity,	 in	 which	 the	 trifluoro	 methyl	 group	 is	
attached	 to	 the	 meta	 position	 which	 is	 highly	 electron	
withdrawing.	 Compound	 3a	 shows	 the	 least	 antioxidant	
activity,	which	does	not	having	any	substitution.	
	
Table	2.	Antioxidant	activity	of	synthesized	compounds.	
Sample	 Antioxidant	percentage,	5	mg/mL	
3a 14
3b 22
3c 21
3d 16
3e 16
3f	 16	
3g	 31	
3h	 55	
3i 24
3j	 18	
Ascorbic	acid 90
	
	4.	Conclusion	
	
The	 structure	 proposed	 of	 the	 synthesized	 compound	 is	
well	 supported	 by	 spectroscopic	 data.	 From	 the	 data	 of	
antibacterial	 activity	 and	 antioxidant	 activity,	 it	 may	 be	
concluded	that	all	the	synthesized	compounds	possess	good	to	
moderate	activity.		
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